Lung diseases such as fibrosis, viral infection and cancer are life-threatening conditions for which our knowledge on etiology and/or effective treatment options still contains important gaps. To unravel disease processes and to test novel therapeutic approaches, investigators typically rely on end-stage procedures (such as serum analysis, cyto-/chemokine profiles and selective tissue histology from animal models). These techniques are useful but provide only a snapshot of disease processes that are essentially dynamic in time and space. Technology allowing evaluation of live animals repeatedly is indispensable to gain better insight into the dynamics of lung disease progression and treatment. Computed tomography (CT) is a clinical standard and can have enormous benefits in a research context too. Yet, its implementation in basic and preclinical research laboratories lags behind. Nevertheless, the evidence for the benefits of micro-CT as an indispensable and safe tool to repeatedly evaluate lung disease progression and therapy efficacy in live animals is nothing but convincing.
This webinar took place on July 9th, 2020
Basic, translational and clinical researchers in the field of lung disease research and preclinical therapy trials
Dr Greetje Vande Velde
Assistant Professor, KU Leuven
Kjell Laperre, PhD
Micro-CT Market Product & Applications Manager in the Bruker Biospin Pre-Clinical Imaging Division